Overview

Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Xigen SA